Patient and donor characteristics
Characteristic . | Data . |
|---|---|
| Median recipient age, y (range) | 49 (18-63) |
| Sex | |
| Recipient, no. male/no. female (% male/% female) | 58/55 (51/49) |
| Female donor, no. (%) | 52 (46) |
| Negative CMV donor-recipient pair, no. (%) | 18 (16) |
| ABO incompatibility, no. (%) | 42 (37) |
| Diagnosis, no. (%) | |
| Acute myeloblastic leukemia | 32 (28) |
| Myelodysplastic syndrome | 4 (4) |
| Chronic myeloid leukemia | 6 (5) |
| Non-Hodgkin lymphoma | 19 (17) |
| Hodgkin lymphoma | 3 (3) |
| Multiple myeloma | 20 (18) |
| Chronic lymphocytic leukemia | 3 (3) |
| Metastatic solid tumor | 26 (23) |
| Disease status, no. (%) | |
| Standard risk* | 23 (20) |
| Advanced disease | 90 (80) |
| Conditioning regimen, no. (%) | |
| ATG-based regimen6,9 | 80 (71) |
| Low-dose irradiation-based regimen | 33 (29) |
| GVHD prophylaxis, no. (%) | |
| CSA alone | 70 (62) |
| CSA + mycophenolate mofetil | 43 (38) |
| Graft source, no. (%) | |
| Peripheral blood stem cells | 108 (96) |
| Bone marrow | 5 (4) |
| Graft composition, median (range) | |
| CD34+, × 106/kg recipient body weight | 6.0 (1.4-37.0) |
| CD3+, × 106/kg recipient body weight | 327 (14-888) |
Characteristic . | Data . |
|---|---|
| Median recipient age, y (range) | 49 (18-63) |
| Sex | |
| Recipient, no. male/no. female (% male/% female) | 58/55 (51/49) |
| Female donor, no. (%) | 52 (46) |
| Negative CMV donor-recipient pair, no. (%) | 18 (16) |
| ABO incompatibility, no. (%) | 42 (37) |
| Diagnosis, no. (%) | |
| Acute myeloblastic leukemia | 32 (28) |
| Myelodysplastic syndrome | 4 (4) |
| Chronic myeloid leukemia | 6 (5) |
| Non-Hodgkin lymphoma | 19 (17) |
| Hodgkin lymphoma | 3 (3) |
| Multiple myeloma | 20 (18) |
| Chronic lymphocytic leukemia | 3 (3) |
| Metastatic solid tumor | 26 (23) |
| Disease status, no. (%) | |
| Standard risk* | 23 (20) |
| Advanced disease | 90 (80) |
| Conditioning regimen, no. (%) | |
| ATG-based regimen6,9 | 80 (71) |
| Low-dose irradiation-based regimen | 33 (29) |
| GVHD prophylaxis, no. (%) | |
| CSA alone | 70 (62) |
| CSA + mycophenolate mofetil | 43 (38) |
| Graft source, no. (%) | |
| Peripheral blood stem cells | 108 (96) |
| Bone marrow | 5 (4) |
| Graft composition, median (range) | |
| CD34+, × 106/kg recipient body weight | 6.0 (1.4-37.0) |
| CD3+, × 106/kg recipient body weight | 327 (14-888) |
N = 113 patients and donors.
CMV indicates cytomegalovirus.
Standard risk disease: chronic myeloid leukemia in chronic phase, acute leukemia in first complete remission